The toxicology of heparin reversal with protamine: past, present and future

Preparation and evaluation a new generation of low molecular weight heparin

(2016) Dan Zhao et al.   BIOMEDICINE & PHARMACOTHERAPY

Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial

(2016) A Michael Lincoff et al.   LANCET

The Toxicokinetic Profile of Dex40-GTMAC3—a Novel Polysaccharide Candidate for Reversal of Unfractionated Heparin

(2016) Emilia Sokolowska et al.   Frontiers in Pharmacology

Les différentes alternatives d’anticoagulation au couple héparine/protamine en chirurgie cardiaque sous circulation extra-corporelle

(2015) Aurore Bouraghda et al.   Canadian Journal of Anesthesia-Journal canadien d anesthesie

Serological features of antibodies to protamine inducing thrombocytopenia and thrombosis

(2015) Simon Panzer et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

Reversal of Heparin After Cardiac Surgery: Protamine Titration Using a Statistical Model

(2015) Fredrik Ödling Davidsson et al.   JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA

Safety and efficacy outcomes of protamine administration for heparin reversal following cryoballoon-based pulmonary vein isolation

(2015) Kadri Murat Gurses et al.   JOURNAL OF INTERVENTIONAL CARDIAC ELECTROPHYSIOLOGY

Platelet-activating protamine-heparin-antibodies lead to higher protamine demand in patients undergoing cardiac surgery

(2015) Philippe Grieshaber et al.   JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY

Idarucizumab for Dabigatran Reversal

(2015) Charles V. Pollack et al.   NEW ENGLAND JOURNAL OF MEDICINE

Protamine reduces whole blood platelet aggregation after cardiopulmonary bypass

(2015) Anki Olsson et al.   SCANDINAVIAN CARDIOVASCULAR JOURNAL

Nonclinical Evaluation of Novel Cationically Modified Polysaccharide Antidotes for Unfractionated Heparin

(2015) Bartlomiej Kalaska et al.   PLoS One

Low molecular weight protamine (LMWP): A nontoxic protamine substitute and an effective cell-penetrating peptide

(2014) Huining He et al.   JOURNAL OF CONTROLLED RELEASE

Inactivation of Heparin by Cationically Modified Chitosan

(2014) Barbara Lorkowska-Zawicka et al.   Marine Drugs

Use of PER977 to Reverse the Anticoagulant Effect of Edoxaban

(2014) Jack E. Ansell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adenovirus-Mediated Gene Transfer in Mesenchymal Stem Cells Can Be Significantly Enhanced by the Cationic Polymer Polybrene

(2014) Chen Zhao et al.   PLoS One

Affinity-based design of a synthetic universal reversal agent for heparin anticoagulants

(2014) R. A. Shenoi et al.   Science Translational Medicine

Anti-protamine-heparin antibodies: incidence, clinical relevance, and pathogenesis

(2013) T. Bakchoul et al.   BLOOD

High incidence of antibodies to protamine and protamine/heparin complexes in patients undergoing cardiopulmonary bypass

(2013) G. M. Lee et al.   BLOOD

Heparin sensing and binding – taking supramolecular chemistry towards clinical applications

(2013) Stephen M. Bromfield et al.   CHEMICAL SOCIETY REVIEWS

A 1-year drug utilization evaluation of protamine in hospitalized patients to identify possible future roles of heparin and low molecular weight heparin reversal agents

(2013) Charles E. Mahan   JOURNAL OF THROMBOSIS AND THROMBOLYSIS

A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa

(2013) Genmin Lu et al.   NATURE MEDICINE

A Case Series of Recombinant Platelet Factor 4 for Heparin Reversal After Cardiopulmonary Bypass

(2012) Linda Demma et al.   ANESTHESIA AND ANALGESIA

Cationic derivative of dextran reverses anticoagulant activity of unfractionated heparin in animal models of arterial and venous thrombosis

(2012) Bartlomiej Kalaska et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Efficient enhancement of lentiviral transduction efficiency in murine spermatogonial stem cells

(2012) Bang-Jin Kim et al.   MOLECULES AND CELLS

Cationic Derivatives of Dextran and Hydroxypropylcellulose as Novel Potential Heparin Antagonists

(2011) Kamil Kamiński et al.   JOURNAL OF MEDICINAL CHEMISTRY

Engineered virus-like nanoparticles reverse heparin anticoagulation more consistently than protamine in plasma from heparin-treated patients

(2011) Andrew J. Gale et al.   THROMBOSIS RESEARCH

Heparin modifies the immunogenicity of positively charged proteins

(2010) S. L. Chudasama et al.   BLOOD

Allergic shock and death associated with protamine administration in a diabetic patient

(2010) Yan-Qi Chu et al.   CLINICAL THERAPEUTICS

Reversal of heparin-induced increases in aPTT in the rat by PM102, a novel heparin antagonist

(2010) Daniel J. Cushing et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Review: Anticoagulation for haemodialysis

(2010) MICHAEL SURANYI et al.   NEPHROLOGY

Safety of Recombinant Activated Factor VII in Randomized Clinical Trials

(2010) Marcel Levi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Protamine sulfate down-regulates thrombin generation by inhibiting factor V activation

(2009) F. Ni Ainle et al.   BLOOD

Hydrogen peroxide affects contractile activity and anti-oxidant enzymes in rat uterus

(2009) I Appiah et al.   BRITISH JOURNAL OF PHARMACOLOGY

Incidence and outcomes of protamine reactions in patients undergoing catheter ablation of atrial fibrillation

(2009) Karuna Chilukuri et al.   JOURNAL OF INTERVENTIONAL CARDIAC ELECTROPHYSIOLOGY

Effect of protamine sulfate on the isolated mesenteric arteries of normotensive and spontaneously hypertensive rats

(2008) Zorana Orescanin-Dusic et al.   Archives of Biological Sciences

Serious Anaphylactic Reactions due to Protamine Sulfate: A Systematic Literature Review

(2008) Mads Nybo et al.   BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

New Antithrombotic Drugs

(2008) Jeffrey I. Weitz et al.   CHEST

Off-label use of recombinant factor VIIa for treatment of haemorrhage: results from randomized clinical trials

(2008) P. I. Johansson   VOX SANGUINIS